Alirocumab is indicated for:
Irrespective of gender only Adults (18 years old or older)
Alirocumab is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
The effect of alirocumab on cardiovascular morbidity and mortality has not yet been determined.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 years old or older)
Alirocumab is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
For this indication, the medical literature mentions below treatments (click for details):